市场调查报告书
商品编码
1271366
气管插管市场规模、市场份额、应用分析、区域展望、增长趋势、主要参与者、竞争战略、预测,2023-2031 年Endotracheal Tubes Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031 |
在 2023 年至 2031 年的预测期内,全球气管导管市场预计将以 6.5% 的复合年增长率增长。 心血管疾病、癌症和其他呼吸系统疾病等慢性病的增加增加了需要气管插管的外科手术的数量。 根据世界卫生组织 2019 年的一份报告,呼吸系统疾病是全球死亡的主要原因,每年约有 400 万人死亡。 因此,预计该市场在未来几年将出现有利可图的增长。
手术次数的增加推动了对气管插管的需求。 根据《全球外科和麻醉统计》报告,每年大约进行 31.3 亿次外科手术。 气管插管技术的进步不仅降低了与插管相关的感染风险,还提高了产品安全性。 使用气管导管或呼吸机超过 48 小时的患者最有可能发生呼吸机相关性肺炎 (VAP),并且这种疾病呈上升趋势。 因此,许多市场进入者正在努力开发具有抗菌和抗凝涂层的产品,以减少 VAP。 例如,据报导 Medtronic Shiley Evac 气管插管可将 VAP 降低 50.0%。 因此,随着 VAP 发病率的增加,对涂层气管插管的需求也在增加,从而刺激了市场的扩张。 因此,气管插管技术的进步和更容易患许多慢性病的人口老龄化预计将在预测期内增加市场增长机会。
由于呼吸困难是传染病的明显征兆,COVID-19 的出现显着增加了对气管插管的需求,推动了市场扩张。 对于 COVID 患者的呼吸衰竭,美国支气管学会建议采用开放式外科气管切开术 (OST) 或经皮扩张气管切开术。 大流行使紧急产品批准成为可能。 美国生物技术公司 N8 的 CeraShield 气管导管已获得加拿大卫生部的紧急使用授权,用于机械通气的 COVID-19 患者。 该公司的专利防污涂层旨在防止致命的细菌感染。 气管插管和机械通气可帮助 COVID-19 患者在免疫系统对抗病毒的同时呼吸并维持生命。 这将增加您成功对抗病毒的机会。 这种情况有望刺激市场扩张。
为防止医院感染,製造商正在努力开发创新的气管插管。 例如,2 月,N8 Medical, LLC 向 FDA 提交了 IDE(调查设备豁免),以进行 CeraShield 气管内插管 (ETT) 的首次人体临床试验。 该临床试验的目的是评估 CeraShield 气管插管 (ETT) 的安全性和有效性。
医院因机械通气引起的肺炎等感染正在推动插管市场的增长。 重症监护病房因手术并发症而导致患者死亡的风险最高,其中之一是院内感染等继发过程引起的病情加重。
到 2022 年,常规气管插管细分市场占据主导地位,收入份额最大,达到 32.5%,这是由于与呼吸系统疾病患病率上升相关的外科手术增加。 随着 VAP 发病率的增加,预计未来对气管插管的需求也会增加。 因此,预计该行业在预测期内将呈现有利可图的增长。 市场按产品类型分为常规气管插管、强化气管插管、高性能气管插管和双腔气管插管。
到 2022 年,气管造口术细分市场的收入份额最大,达到 65%。 根据路线类型,市场分为气管内和经鼻气管。 气管插管以其适用性广、利用率高、舒适度高等优点占据了最大的市场份额。 气管插管用于保护所有手术患者的气道。 也用于重伤患者和合併多器官疾病的危重患者。
到 2022 年,急症护理领域占市场的最大收入份额,达到 55%。 市场进一步细分为急性护理、治疗和其他应用。 这一部分的最大份额可归因于心臟骤停、呼吸、气道阻塞和通风不足等紧急情况发生率的上升、交通事故事件的增加以及发展中国家可支配收入的增加。 然而,预计治疗领域在预测期内将经历更大的增长。 在预测期内,这一领域的增长预计将主要受到外科手术增加、慢性呼吸道疾病流行和人口老龄化的推动。
2022 年,由于全球住院趋势,医院部门的收入份额最大,超过 35%。 该市场按最终用户细分为医院、门诊手术中心、诊所等。 此外,医院医生和护理人员的高度认可也促进了这一领域市场份额的增长。 预计诊所市场将在预测期内实现最大增长。 慢性呼吸系统疾病的增加、诊所福利意识的提高以及公平的报销政策推动了这一细分市场的扩张。 然而,由于北美和亚太地区的中心扩张,预计门诊手术中心在预测期内也将出现显着增长。
由于先进的医疗保健系统和慢性病患病率上升,北美在 2022 年主导了气管插管市场,占全球收入的 35% 以上。 该地区也有重要的市场进入者,这有助于扩大市场。 Teleflex Incorporated、Medline Industries 和 Medtronic 是该地区最着名的三家公司。
快速采用先进的医疗保健技术来增强医疗保健已成为影响市场竞争力的关键因素。 除了推出新产品外,大公司还经常进行併购以保持市场份额并使产品组合多样化。 Medtronic Plc、Teleflex Inc、ConvaTec Inc、Smiths Medical、Neurovision Medical Products、Intersurgical Inc、Royax、Novo Klinik-Service GmbH、Avanos Medical, Inc、Bactiguard、N8 Medical LLC 和其他知名企业正在引领气管插管市场。的主要参与者
The global endotracheal tube market is projected to expand at a CAGR of 6.5% during the forecast period of 2023 to 2031. Increasing incidences of chronic diseases such as cardiovascular disease, cancer, and other respiratory diseases have led to an increase in the number of surgical procedures requiring endotracheal tubes. According to the 2019 World Health Organization report, respiratory diseases are the leading cause of death worldwide, accounting for approximately 4.0 million deaths annually. Consequently, the market is anticipated to exhibit lucrative growth over the coming years.
The demand for endotracheal tubes has been fuelled by an increase in the number of surgeries. According to the report Global Surgery and Anaesthesia Statistics, approximately 313,0 million surgical procedures are performed annually. In addition to reducing the risk of infection associated with tubes, technological advances in endotracheal intubation have enhanced product safety. Patients who have been on an endotracheal tube or mechanical ventilator for more than 48 hours are the most likely to develop Ventilator-Associated Pneumonia (VAP), a condition that has been on the rise. Thus, numerous market participants are developing products with antimicrobial and anticoagulant coatings that can reduce VAP. For instance, it has been reported that Medtronic Shiley Evac endotracheal tubes reduce VAP by 50.0%. Consequently, as the incidence of VAP rises, so does the demand for coated endotracheal tubes, fueling the market's expansion. Consequently, technological advancements in endotracheal tubes and an aging population that is increasingly susceptible to numerous chronic diseases will increase the market's growth opportunities during the forecast period.
As breathing difficulty is a clear indication of infection, the emergence of COVID-19 has greatly increased the demand for endotracheal tubes, which has fueled the market expansion. In cases of respiratory failure in COVID patients, the American Association for Bronchology and Interventional Pulmonology suggests Open Surgical Tracheostomy (OST) or percutaneous dilatational tracheostomy. This pandemic made emergency product approvals possible. N8, a U.S.-based biotechnology company, obtained emergency use authorization from Health Canada for its CeraSheild Endotracheal Tubes in COVID-19 patients receiving mechanical ventilation. The anti-fouling coating on the company's patented product is designed to prevent deadly bacterial infections. Endotracheal intubation and ventilation support a COVID-19 patient's breathing so that the patient can survive while the immune system battles the virus. This increases the likelihood of successfully combating the virus. Such scenarios are anticipated to stimulate market expansion
Increased launches and approvals of advanced and efficient endotracheal tubes by key players are anticipated to propel the endotracheal tube market over the coming years. In November 2016, Bactiguard introduced the BIP Endotracheal Tube Evac to prevent ventilator-associated pneumonia in patients (VAP). To prevent ventilator-associated pneumonia (VAP) infections, the innovative BIP Endotracheal Tube Evac has subglottic secretion drainage and a Bactiguard coating.
In order to prevent hospital-acquired infections, manufacturers are emphasizing the creation of innovative endotracheal tubes. For instance, in February, N8 Medical, LLC submitted to the Food and Drug Administration (FDA) the Investigational Device Exemption (IDE) for the first-in-human clinical study of its CeraShield Endotracheal Tube (ETT). The purpose of the clinical trial is to assess the safety and effectiveness of the CeraShield Endotracheal Tube (ETT).
Nonetheless, the increasing prevalence of hospital-acquired infections, such as ventilator-associated pneumonia, is anticipated to restrain the growth of the endotracheal tube market during the forecast period. According to the National Center for Biotechnology Information, the incidence of ventilator-associated pneumonia (VAP) in the United States ranged from 2 to 16 episodes per 1,000 ventilator days in November 2017.
Hospitals that have acquired infections such as pneumonia associated with mechanical ventilation are driving the growth of the intubation tube market. In intensive care units, patients are at the highest risk of death due to procedure complications or other causes, one of which is a critical illness caused by secondary processes, such as nosocomial infection.
Pneumonia, which affects 27% of critically ill patients, is the second most common nosocomial infection, after urinary tract infections. Nearly 86% of nosocomial pneumonia is caused by pneumonia associated with mechanical ventilation.
Mortality associated with ventilator-associated pneumonia has been estimated to range between 0% and 50%. When it comes to assessing attributable mortality, different studies have yielded divergent results due to the diversity of the populations examined.
In 2022, the segment of regular endotracheal tubes dominated the market and held the largest revenue share of 32.5% due to the increasing number of surgical procedures as a result of the rising prevalence of respiratory diseases. Also, as the incidence of VAP rises, the demand for endotracheal tubes is anticipated to increase in the future. As a result, the segment is anticipated to exhibit lucrative growth over the forecast period. The market has been divided into regular endotracheal tubes, reinforced endotracheal tubes, performed endotracheal tubes, and double-lumen endotracheal tubes based on the type of product.
However, the reinforced endotracheal tube segment is expected to grow at a faster rate over the forecast period due to its increasing use during surgery and recent technological advancements in endotracheal tubes. In addition, the increasing incidence of road accidents and trauma injuries will contribute to the segment's growth over the forecast period.
In 2022, the orotracheal segment held the largest revenue share of 65% of the market. The market has been classified as orotracheal and nasotracheal based on route type. Orotracheal has the largest market share due to its broad applicability, increased utilization, and comfort. Orotracheal intubation is utilized to control the airway of any surgical patient. It is also used for patients with severe injuries or multisystem diseases who are critically ill.
Orotracheal incubation is commonly used in emergency situations such as respiratory or cardiac arrest, inadequate oxygenation or ventilation, failure to protect the airway from aspiration, and existing or anticipated airway obstruction. Due to this, the demand for orotracheal tubes has increased over the past few years, and the segment is expected to grow at a healthy rate over the forecast period. Additionally, the aforementioned factors will increase demand for orotracheal intubation over the forecast period. Due to the rising prevalence of respiratory disease, it is anticipated that the nasotracheal segment will experience the highest CAGR of 5.6% during the forecast period.
In 2022, the emergency treatment segment held the largest revenue share of 55% of the market. The market is further segmented by application into emergency treatment, therapy, and others. The largest share of this segment can be attributed to the rising incidence of emergency conditions such as cardiac arrest and respiratory, airway obstruction and inadequate ventilation, rising cases of road accidents, and growing disposable income in developing nations. Nonetheless, the therapy segment is anticipated to experience greater growth during the forecast period. During the forecast period, the segment's growth will be driven primarily by the increasing volume of surgical procedures, the prevalence of chronic respiratory diseases, and the aging population.
In 2022, the hospital's segment held the largest revenue share at over 35% due to the global trend toward hospitalization. The market has been segmented by end-use into hospitals, ambulatory surgical centers, clinics, and others. In addition, high awareness among hospital physicians and nursing staff contributes to the segment's increasing market share. The clinics market segment is anticipated to experience the greatest growth during the forecast period. The increasing prevalence of chronic respiratory diseases, rising awareness of the benefits of clinics, and equitable reimbursement policies will drive the expansion of this market segment. However, ambulatory surgical centers are also anticipated to experience significant growth over the forecast period due to the expansion of centers in North America and Asia-Pacific.
Due to its advanced healthcare system and rising prevalence of chronic diseases, North America dominated the endotracheal tubes market in 2022, accounting for more than 35% of the global revenue. In addition, the presence of significant market participants in the region contributed to market expansion. Teleflex Incorporated, Medline Industries, and Medtronic are three of the region's most prominent companies.
In 2022, the United States contributed over 30% of the global Intubation Tube Market revenue. The increase in tracheal diseases, such as tracheal stenosis, bronchial tumors, and tracheobronchomalacia, has increased the country's demand for intubation tubes. The National Cancer Institute estimates that there will be 236 740 new cases of lung and bronchial cancer in the United States in 2022, which represents 12.3% of all new cancer cases. This will bring the death toll for this disorder to 130,180, or 21.4% of all cancer-related deaths in the country.
Asia-Pacific is anticipated to experience the market's fastest growth over the forecast period. The increasing geriatric population with respiratory disease, rising prevalence of ventilator-associated pneumonia, and rising number of surgeries due to chronic cardiovascular disease are expected to increase regional demand for endotracheal tubes.
The rapid adoption of advanced healthcare technology for enhanced healthcare is a crucial factor influencing the market's competitiveness. In addition to new product launches, major players frequently engage in mergers and acquisitions in order to retain market share and diversify their product portfolios. Medtronic Plc, Teleflex Inc., ConvaTec Inc., Smiths Medical, Neurovision Medical Products, Intersurgical Inc., Royax, Novo Klinik-Service GmbH, Avanos Medical, Inc., Bactiguard, N8 Medical LLC and Other Notable Players are some of the key players in the endotracheal tube market.
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Endotracheal Tubes market are as follows:
Micro and macro environment factors that are currently influencing the Endotracheal Tubes market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.